Article
dsAAV type 2-mediated gene transfer of MORS196A-EGFP into spinal cord as a pain management paradigm.
Proceedings of the National Academy of Sciences of the United States of America - 11 Dec 2007
Chen S L, Ma H I, Han J M, Tao P L, Law P Y, Loh H H
Abstract excerpt
We previously reported that mutations in the mu-opioid receptor (MOR), S196L or S196A, rendered MOR responsive to the opioid antagonist naloxone without altering the agonist phenotype. Subsequently, a mouse strain carrying the S196A mutation exhibited in vivo naloxone antinociceptive activity without the development of tolerance. In this study we investigated the possibility of combining the in vivo site-directed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.